Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Grants and contracts	$ 8,790,209	$ 15,331,567	$ 12,695,908
Service			1,650,000
Total revenues	8,790,209	15,331,567	14,345,908
Operating expenses:
Research and development	22,788,887	16,141,040	14,331,673
General and administrative	11,106,493	9,927,725	6,397,164
Total operating expenses	33,895,380	26,068,765	20,728,837
Loss from operations	(25,105,171)	(10,737,198)	(6,382,929)
Other income (expense):
Interest income	183,662	99,111	19,728
Other expense	(130,003)	(22,001)	(195,543)
Change in value of warrant liability	19,821,787	(16,011,769)	(6,267,665)
Total other income (expense)	19,875,446	(15,934,659)	(6,443,480)
Net loss	(5,229,725)	(26,671,857)	(12,826,409)
Net loss attributable to noncontrolling interests	1,216,055	305,812
Net loss attributable to Cleveland BioLabs, Inc.	(4,013,670)	(26,366,045)	(12,826,409)
Dividends on convertible preferred stock			615,351
Net loss available to common stockholders	$ (4,013,670)	$ (26,366,045)	$ (13,441,760)
Net loss available to common stockholders per share of common stock, basic and diluted (in Dollars per share)	$ (0.12)	$ (1.01)	$ (0.82)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares)	32,561,743	26,184,773	16,405,129